| Literature DB >> 27812520 |
Kook Hyun Kim1, Tae Nyeun Kim1.
Abstract
Objective. Bile duct stone-related adverse events can be detrimental in the elderly. However, little is known about clinical outcomes and adverse events following endoscopic papillary large balloon dilation (EPLBD) in the elderly. The aim of this study was to evaluate the safety and feasibility of EPLBD for the removal of CBD stones in patients aged ≥ 80 years. Methods. A total of 204 patients who underwent EPLBD from 2006 to 2012 were retrospectively reviewed. Patients were classified into two groups (148 patients < 80 years old, Group A; 56 patients ≥ 80 years old, Group B). Endoscopic findings, clinical outcomes, and adverse events in two groups were compared. Results. The number of underlying chronic diseases in Group B was significantly higher than in Group A (P = 0.032). The rates of overall stone clearance were similar between two groups (P = 0.145). No significant difference with regard to post-ERCP pancreatitis between two groups was observed (P = 0.687). All episodes of pancreatitis had full recovery with conservative treatment. One major hemorrhage in Group A was successfully controlled endoscopically and one death caused by retroperitoneal perforation occurred in Group A. Conclusions. EPLBD appear to be safe and effective for CBD stone removal in patients aged ≥ 80 years.Entities:
Mesh:
Year: 2016 PMID: 27812520 PMCID: PMC5080473 DOI: 10.1155/2016/6568989
Source DB: PubMed Journal: Can J Gastroenterol Hepatol ISSN: 2291-2789
Demographics and baseline characteristics.
| Variables | Total ( | <80 yr ( | ≥80 yr ( |
|
|---|---|---|---|---|
| Age (years, range) | 73.0 ± 9.6 (50–92) | 68.5 ± 7.4 (50–79) | 84.5 ± 3.1 (80–92) | <0.001 |
| Sex (M) | 107 (52.5) | 89 (60.1) | 18 (32.1) | <0.001 |
| BMI (kg/m2) | 22.4 ± 3.2 | 22.5 ± 3.1 | 22.0 ± 3.4 | 0.261 |
| With ES | 116 (56.9) | 80 (54.1) | 36 (64.3) | <0.001 |
| Precutting | 28 (13.7) | 22 (14.9) | 6 (10.7) | 0.442 |
| Previous surgery | ||||
| Cholecystectomy | 29 (14.2) | 21 (14.2) | 8 (14.3) | 0.986 |
| Billroth II gastrectomy | 35 (17.2) | 29 (19.6) | 6 (10.7) | 0.133 |
| Underlying chronic disease | 110 (53.9) | 73 (49.3) | 37 (66.1) | 0.032 |
| Neurologic | ||||
| CVA | 20 (9.8) | 17 (11.5) | 3 (5.4) | 0.291 |
| Dementia | 6 (2.9) | 0 | 6 (10.7) | <0.001 |
| Hypertension | 84 (41.2) | 56 (37.8) | 28 (50.0) | 0.115 |
| Cardiovascular | ||||
| Coronary heart disease | 12 (5.9) | 7 (4.7) | 5 (8.9) | 0.255 |
| Congestive heart failure | 9 (4.4) | 6 (4.1) | 3 (5.4) | 0.708 |
| Chronic renal failure | 5 (2.5) | 4 (2.7) | 1 (1.8) | 1.000 |
| Liver cirrhosis | 7 (3.4) | 7 (4.7) | 0 | 0.193 |
| COPD | 9 (4.4) | 4 (2.7) | 5 (8.9) | 0.118 |
| Periampullary diverticulum | 102 (50.0) | 68 (45.9) | 34 (60.7) | 0.060 |
| Large diverticulum (>3 cm) | 26 (12.7) | 13 (8.8) | 13 (23.2) | 0.006 |
| Gallstones | 85 (41.7) | 60 (40.5) | 25 (44.6) | 0.596 |
| CBD stones | ||||
| Number (1/2/≥3) | 101/33/70 | 75/25/48 | 26/8/22 | 0.434 |
| Size of stones (mm, range) | 16.0 ± 5.7 (10–37) | 15.6 ± 5.6 (10–35) | 17.1 ± 6.0 (10–37) | 0.094 |
| Type (brown/black/cholesterol) | 38/166/204 | 131/132/1 | 47/7/1 | 0.285 |
| CBD pathology | ||||
| CBD diameter (mm, range) | 19.8 ± 5.3 (9.1–35.5) | 19.4 ± 5.1 (9.1–35.5) | 21.0 ± 5.5 (10.2–35.2) | 0.052 |
| Distal CBD stricture | 11 (5.4) | 8 (5.4) | 3 (5.4) | 0.989 |
| Size of balloon dilator (mm, range) | 15.4 ± 2.4 (12–20) | 15.3 ± 2.4 (12–20) | 15.7 ± 2.3 (12–20) | 0.275 |
| Duration of balloon (mm, range) | 38.0 ± 16.1 (10–60) | 38.6 ± 16.7 (10–60) | 36.3 ± 14.5 (10–60) | 0.321 |
BMI: body mass index; ES: endoscopic sphincterotomy; CVA: cerebrovascular accident; COPD: chronic obstructive pulmonary disease; CBD: common bile duct. Values are presented as mean ± SD (range) or as numbers (%).
Clinical outcomes of endoscopic retrograde cholangiopancreatography.
| Variables | Total ( | <80 years ( | ≥80 years ( |
|
|---|---|---|---|---|
| Overall stone clearance | 196 (96.1) | 144 (97.3) | 52 (92.9) | 0.145 |
| Number of sessions of endoscopy | ||||
| 1 | 143 (70.1) | 101 (68.2) | 42 (75.0) | 0.682 |
| 2 | 51 (25.0) | 41 (27.7) | 10 (17.9) | |
| ≥3 | 10 (4.9) | 6 (4.1) | 4 (7.1) | |
| Stent placement | ||||
| ENBD | 38 (18.6) | 27 (18.2) | 11 (19.6) | 0.819 |
| ERBD | 33 (16.2) | 24 (16.2) | 9 (16.1) | 0.980 |
| Mechanical lithotripsy | 19 (9.3) | 13 (8.8) | 6 (10.7) | 0.672 |
| Pancreatogram | 46 (22.5) | 36 (24.3) | 10 (17.9) | 0.324 |
ENBD: endoscopic nasobiliary drainage; ERBD: endoscopic retrograde biliary drainage. Values are presented as numbers (%).
Postprocedural adverse events between two groups.
| Variables | <80 years ( | ≥80 years ( |
|
|---|---|---|---|
| Total | 9 (6.1) | 3 (5.4) | 1.000 |
| Pancreatitis | 5 (3.4) | 3 (5.4) | 0.687 |
| Mild | 4 (80.0) | 2 (66.7) | |
| Moderate | 1 (20.0) | 1 (33.3) | |
| Acute cholangitis | 2 (1.4) | 0 | 1.000 |
| Acute cholecystitis | 1 (0.7) | 0 | 1.000 |
| Bleeding | 3 (2.1) | 0 | 0.313 |
| Major | 1 (0.7) | 0 | |
| Minor | 2 (1.4) | 0 | |
| Perforation | 1 (0.7) | 0 | 1.000 |
| Mortality | 1 (0.7) | 0 | 1.000 |
Values are presented as numbers (%).